» Articles » PMID: 32435939

The Emerging Role of Wnt5a in the Promotion of a Pro-inflammatory and Immunosuppressive Tumor Microenvironment

Overview
Specialty Oncology
Date 2020 May 22
PMID 32435939
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Wnt5a is the prototypical activator of the non-canonical Wnt pathways, and its overexpression has been implicated in the progression of several tumor types by promoting cell motility, invasion, EMT, and metastasis. Recent evidences have revealed a novel role of Wnt5a in the phosphorylation of the NF-κB subunit p65 and the activation of the NF-κB pathway in cancer cells. In this article, we review the molecular mechanisms and mediators defining a Wnt5a/NF-κB signaling pathway and propose that the aberrant expression of Wnt5a in some tumors drives a Wnt5a/NF-κB/IL-6/STAT3 positive feedback loop that amplifies the effects of Wnt5a. The evidences discussed here suggest that Wnt5a has a double effect on the tumor microenvironment. First, it activates an autocrine ROR1/Akt/p65 pathway that promotes inflammation and chemotaxis of immune cells. Then, Wnt5a activates a TLR/MyD88/p50 pathway exclusively in myelomonocytic cells promoting the synthesis of the anti-inflammatory cytokine IL-10 and a tolerogenic phenotype. As a result of these mechanisms, Wnt5a plays a negative role on immune cell function that contributes to an immunosuppressive tumor microenvironment and would contribute to resistance to immunotherapy. Finally, we summarized the development of different strategies targeting either Wnt5a or the Wnt5a receptor ROR1 that can be helpful for cancer therapy by contributing to generate a more immunostimulatory tumor microenvironment.

Citing Articles

Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review.

Anand S, Patel T Discov Oncol. 2024; 15(1):779.

PMID: 39692821 PMC: 11655924. DOI: 10.1007/s12672-024-01662-1.


Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment.

Zhang H, Li S, Wang D, Liu S, Xiao T, Gu W Biomark Res. 2024; 12(1):96.

PMID: 39227970 PMC: 11373140. DOI: 10.1186/s40364-024-00646-1.


Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer.

Choi S, Pan E, Elliott A, Beltran H, Panian J, Jamieson C Mol Cancer Res. 2024; 22(10):920-931.

PMID: 38912907 PMC: 11850019. DOI: 10.1158/1541-7786.MCR-24-0395.


Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density.

Wohlfarth J, Kosnopfel C, Faber D, Berthold M, Siedel C, Bernhardt M Mol Oncol. 2024; 18(10):2449-2470.

PMID: 38807304 PMC: 11459041. DOI: 10.1002/1878-0261.13660.


Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications.

Yang D, Wang M, Zhang C, Wang Y Front Endocrinol (Lausanne). 2024; 15:1359255.

PMID: 38645427 PMC: 11026568. DOI: 10.3389/fendo.2024.1359255.


References
1.
van Amerongen R, Nusse R . Towards an integrated view of Wnt signaling in development. Development. 2009; 136(19):3205-14. DOI: 10.1242/dev.033910. View

2.
van Amerongen R . Alternative Wnt pathways and receptors. Cold Spring Harb Perspect Biol. 2012; 4(10). PMC: 3475174. DOI: 10.1101/cshperspect.a007914. View

3.
Mikels A, Nusse R . Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006; 4(4):e115. PMC: 1420652. DOI: 10.1371/journal.pbio.0040115. View

4.
Kumawat K, Gosens R . WNT-5A: signaling and functions in health and disease. Cell Mol Life Sci. 2015; 73(3):567-87. PMC: 4713724. DOI: 10.1007/s00018-015-2076-y. View

5.
Moon R, Brown J, Torres M . WNTs modulate cell fate and behavior during vertebrate development. Trends Genet. 1997; 13(4):157-62. DOI: 10.1016/s0168-9525(97)01093-7. View